All PlansAdministrativeMedium impact
08.01.32q, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Pharmacy
We identified it
Jul 2, 2026
Summary
Failed to analyze policy change